Enable Injections

Name

Enable Injections

Legal name

Enable Injections, Inc.

Website

https://enableinjections.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Wearable Drug Delivery Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)

akta.pro secondary industries

Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Wearable drug delivery
• On-body injectors
• Subcutaneous delivery systems
• Biologics combination products
• Large-volume injectors

Headquarters

HQ city

Cincinnati

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Device Manufacturing and Supply: Enable manufactures and supplies enFuse devices to pharmaceutical partners for clinical and commercial use. Partners pay transfer price for clinical and commercial supply of enFuse devices.
2. Partnership Licensing and Milestones: Partners obtain exclusive licenses to use enFuse technology with specific therapeutics. Enable receives upfront technology access fees, potential R&D milestones, commercial milestones, product sales, and single digit royalties.
3. Strategic Investment: Enable receives strategic investments from pharmaceutical partners (e.g., $30M from Sanofi in January 2026) to accelerate manufacturing capabilities and supply chain development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Enable Injections develops and manufactures the enFuse wearable drug delivery platform, a hands-free, purely mechanical on-body injector that delivers large volumes (5-25 mL per device, up to 100 mL with four simultaneous devices) of pharmaceutical and biologic therapeutics subcutaneously. The company works with pharmaceutical and biotech partners under licensing and supply agreements, providing devices for clinical trials and commercial combination products.

Differentiator

Problem solved

Functional benefit

Brands

• enFuse: The enFuse wearable drug delivery platform designed to deliver large volumes of medications subcutaneously, featuring hands-free wearable technology for patient self-administration.
• EMPAVELI Injector
• ASPAVELI enFuse
• CirCLIQ

Products and services

• enFuse Wearable Drug Delivery Platform Hands-free, purely mechanical on-body injector for subcutaneous delivery of 5-25 mL of pharmaceuticals and biologics; four devices can be worn simultaneously for up to 100 mL. Designed for at-home or in-clinic self-administration. Supplied to pharmaceutical partners for combination product development and commercialization.
• EMPAVELI Injector First commercial enFuse-based combination product, FDA-approved for at-home self-administration of pegcetacoplan (Apellis) for PNH, C3G, and primary IC-MPGN. Sold by Apellis in the US.
• ASPAVELI enFuse On-Body Delivery System CE-certified enFuse-based combination product for subcutaneous administration of Aspaveli (pegcetacoplan) for patients 12 years and older with PNH, C3G, and primary IC-MPGN; distributed by Sobi across the European Union.
• CirCLIQ On-Body Injector (Sarclisa SC) enFuse-based on-body injector used to deliver Sanofi's Sarclisa (isatuximab) subcutaneous formulation for multiple myeloma; the first anticancer treatment approved in the EU for administration via a portable injector.

Quantifiable outcome

• 100% of surveyed patients preferred enFuse over infusion pump in randomized control trial (SCIg study)
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Aptar Digital HealthcoreTechnology or Integration · 8 April 2026Aptar Digital Health named Enable's preferred digital health partner for enFuse On-Body Delivery System. Partnership delivers companion digital solution including treatment data recording, onboarding modules, injection guidance, patient-reported outcomes, and symptom tracking. Solution expected to launch H2 2026.
• IncytecoreStrategic or Co-development Partner · 27 October 2025Incyte obtained worldwide exclusive license to use enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and myelofibrosis (MF). Enable receives upfront technology access fee, R&D milestones, commercial milestones, and transfer price for device supply.
• Sobi (Swedish Orphan Biovitrum)coreChannel Partner/ Reseller/ Distributor · 12 September 2024Development and distribution agreement for enFuse Injector for subcutaneous delivery of Aspaveli (pegcetacoplan). Sobi distributes ASPAVELI enFuse in European territories. Regulatory approvals obtained in EU (CE Mark 2026), Saudi Arabia, Brazil, South Korea, Canada.
• Serina TherapeuticsminorStrategic or Co-development Partner · 15 May 2024Partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for advanced Parkinson's disease. Serina obtains worldwide exclusive license; Enable receives upfront fees, milestones, royalties. Clinical trial planned for Q4 2025.
• Viridian TherapeuticsminorStrategic or Co-development Partner · 8 May 2023Partnership to support one of Viridian's preclinical programs using enFuse technology for subcutaneous drug delivery.
• Apellis PharmaceuticalscoreStrategic or Co-development Partner · 17 May 2021EMPAVELI Injector (enFuse-based) received FDA approval in 2023 for subcutaneous delivery of pegcetacoplan for paroxysmal nocturnal hemoglobinuria. First commercial enFuse combination product. Apellis commercializes EMPAVELI Injector in the US.
• Roche (Genentech)coreStrategic or Co-development Partner · 20 August 2019Partnership to integrate Roche's proprietary molecules with Enable's enFuse wearable drug-delivery technology, enabling patients to self-administer high-volume subcutaneous injections at home. Partnership expanded in May 2024.
• UCBminorStrategic or Co-development Partner · 13 November 2018Strategic partnership for development of subcutaneous drug delivery solutions using enFuse technology.
• CSLminorStrategic or Co-development Partner · 13 November 2018Strategic partnership for development of subcutaneous drug delivery solutions using enFuse technology.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• West Pharmaceutical Services: West's Device and Containment Solutions unit offers on-body wearable injectors (SmartDose, ContraFLO, and other platforms) for large-volume SC delivery. Closest direct competitor to Enable's enFuse, partnering with multiple large pharma companies across the same therapeutic areas.
• Ypsomed: Swiss device manufacturer with YpsoDose, a 2-step wearable injector for 1–10 mL SC delivery and broader pen/injector platforms. Directly competes for the same large-volume SC partnership deals with pharma companies.
• Stevanato Group: Italian manufacturer offering the On-Body Delivery System (OBDS) for large-volume SC biologics, plus integrated vial and syringe solutions. Directly comparable on-body technology competing for similar pharma combination-product opportunities.
• SHL Medical: Developer of wearable injectors including the Molly and Maggie autoinjector/wearable platforms. Directly comparable large-volume wearable technology competing with enFuse for pharma partnership wins.
• Phillips-Medisize (Molex): Contract developer of drug-delivery devices including on-body wearable injectors for pharma partners. Overlaps with Enable in B2B combination-product development and large-volume SC delivery engineering services.

Broad incumbents

• Becton Dickinson (BD): BD's Pharmaceutical Systems unit offers the Libertas wearable on-body injector plus a broad prefilled syringe and device portfolio. Comparable via large-volume SC combination products; competes from a much larger medtech incumbent position.
• Eli Lilly (delivery platform): Lilly has invested heavily in internal and partnered wearable on-body injector development for large-volume biologics (e.g., insulin, GLP-1, oncology). Competes as a vertically integrated pharma developing or sourcing similar delivery technology.

Emerging players

• Gerresheimer: Primary packaging and drug-delivery device company expanding into on-body injectors and large-volume SC systems. Comparable as a newer entrant building a wearable delivery platform for pharma partners.

Others

• Aptar Pharma: Digital health and drug delivery partner whose Aptar Digital Health division is Enable's preferred digital companion partner. Adjacent/complementary ecosystem participant rather than direct competitor.
• Sanofi (internal delivery): Enable's largest strategic investor and Sarclisa SC partner via CirCLIQ. Sanofi also explores alternative internal and external delivery platforms, making it both a partner and a structural risk to Enable's pipeline concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/enableinjection
• Facebookfacebook.com/EnableInjections
• LinkedInlinkedin.com/company/enable-injections-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enable Injections